Sreenath V. Sharma

Dartmouth–Hitchcock Medical Center

Papers

1

Total Citations

67

H-Index

1

About

Sreenath V. Sharma is a distinguished cancer biologist whose research centers on cell cycle regulation and targeted cancer therapies, with a particular focus on lung cancer. His major contributions include the groundbreaking discovery of "anaphase catastrophe," a novel mechanism of cell death triggered by inhibiting the cyclin E-Cdk-2 complex. In his highly cited 2009 study (67 citations), Sharma demonstrated that targeting this complex not only arrests cancer cell growth but forces them into a catastrophic, premature anaphase, leading to mitotic failure and apoptosis. This work revealed previously unrecognized consequences of cyclin-Cdk inhibition, offering a new therapeutic strategy for lung cancers characterized by deregulated cyclin E expression. Beyond this seminal paper, Sharma's research has significantly advanced our understanding of how cell cycle checkpoints can be exploited for cancer treatment. His findings have implications for developing more effective, targeted therapies that minimize resistance and toxicity. Sharma's work continues to influence both basic cell cycle biology and translational oncology, making him a key figure in the quest for novel lung cancer treatments.

Research Focus

Key Achievements

1
H-Index
1
Papers
67
Total Citations
67
Avg Citations/Paper
🏆 Most Cited Paper
Targeting the Cyclin E-Cdk-2 Complex Represses Lung Cancer Growth by Triggering Anaphase Catastrophe
67 citations · 2009
📈 Most Prolific Year: 2009 (1 Papers)
🤝 Key Collaborators: 11
🏛 Institutions: Dartmouth–Hitchcock Medical Center

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago